<DOC>
	<DOCNO>NCT01492972</DOCNO>
	<brief_summary>The purpose study compare effect , good and/or bad two treatment method subject cancer . Proton beam radiation therapy one treatment men prostate cancer localize disease . The benefit combination androgen suppression completely understood . This study compare use hypofraction proton therapy ( 28 treatment ) alone proton therapy androgen suppression therapy .</brief_summary>
	<brief_title>Hypo-fractionated Radiation Therapy With Without Androgen Suppression Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Histologically confirm prostate adenocarcinoma ( within 365 day randomization ) intermediate risk reoccurrence determine least one following : Gleason Score 7 , PSA &gt; = 10 &lt; = 20 , T stage T2b T2c Clinical stage T1T2c N0 M0 stag treat investigator . ( AJCC Criteria 7th Ed . appendix III ) . Histological evaluation prostate biopsy assignment Gleason score biopsy material ; Gleason score must range 27 . &gt; 6 core strongly recommend . PSA value &lt; = 20 ng/ml within 90 day prior randomization . Obtained prior biopsy least 21 day prostate biopsy . ECOG performance status 01 ( appendix II ) assess within 90 day randomization . Patients must sign IRB approve study specific inform consent . Patients must complete required preentry test list section 4.0 within specify time frame . Patients must able start treatment within 56 day randomization . Patients must least 18 year old . For brachytherapy , IPSS ≤ 21 , ≤ 17 patient medication improve urination . For brachytherapy , prostate volume must less 55cc prior AS . Pelvic lymph node &gt; 1.5 cm great dimension unless enlarge lymph node biopsied negative . Previous prostate cancer surgery include : prostatectomy , hyperthermia cryosurgery . Previous pelvic radiation prostate cancer . Previous androgen suppression therapy prostate cancer . Active rectal diverticulitis , Crohn 's disease affect rectum ulcerative colitis ( nonactive diverticulitis Crohn 's disease affect rectum allow ) . Prior systemic chemotherapy prostate cancer . History proximal urethral stricture require dilatation . Current continue anticoagulation warfarin sodium ( Coumadin ) , heparin , low molecular weight heparin , Clopidogrel bisulfate ( Plavix ) , equivalent ( unless stop manage treatment related toxicity biopsy need ) . Major medical , addictive psychiatric illness investigator 's opinion , prevent consent process , completion treatment and/or interfere followup . ( Consent legal authorize representative permit study ) . Evidence cancer within past 5 year &lt; 50 % probability 5 year survival . ( Prior concurrent diagnosis basal cell noninvasive squamous cell cancer skin allow ) . History myocardial infarction within last 6 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Prostate</keyword>
	<keyword>proton</keyword>
	<keyword>radiation</keyword>
	<keyword>intermediate risk</keyword>
</DOC>